{"transactions":[{"id":822478,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Warrant","published_at":"2026-04-01T16:15:55.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":30978,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 30,978 Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 30,978 Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on the earlier of (ii) December 31, 2029, and (ii) 30 calendars days after the date upon which the Pre-Funded Warrant is exercised, proportional to the amount of such exercise."}],"balance_after":30978,"derivative":{"exercise_price":0.683,"exercise_date":"2026-03-31","underlying":"Common Stock","underlying_shares":30978},"source":{"system":"sec-edgar","filing":"0001104659-26-038522","document":"tm2610878-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926038522/tm2610878-2_4seq1.xml","form_type":"4"}},{"id":822477,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Pre-Funded Warrant","published_at":"2026-04-01T16:15:55.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":30978,"price":0.807,"value":24999.246,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 30,978 Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the \"Beneficial Ownership Limitation\")"}],"balance_after":30978,"derivative":{"exercise_price":0.001,"exercise_date":"2026-03-31","underlying":"Common Stock","underlying_shares":30978},"source":{"system":"sec-edgar","filing":"0001104659-26-038522","document":"tm2610878-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926038522/tm2610878-2_4seq1.xml","form_type":"4"}},{"id":840973,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-16T18:06:04.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":40380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":40380,"derivative":{"exercise_price":0.765,"expiration_date":"2036-03-12","underlying":"Common Stock","underlying_shares":40380},"source":{"system":"sec-edgar","filing":"0001104659-26-028653","document":"tm268953-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926028653/tm268953-1_4seq1.xml","form_type":"4"}},{"id":840972,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2026-03-16T18:06:04.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":10095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":43528,"source":{"system":"sec-edgar","filing":"0001104659-26-028653","document":"tm268953-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926028653/tm268953-1_4seq1.xml","form_type":"4"}},{"id":924457,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Warrant","published_at":"2026-02-02T16:05:34.000Z","date":"2026-01-30","kind":"purchase","planned":false,"acquired":true,"shares":5700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":5700,"derivative":{"exercise_price":0.765,"exercise_date":"2026-01-30","underlying":"Common Stock","underlying_shares":5700},"source":{"system":"sec-edgar","filing":"0001104659-26-009203","document":"tm264801-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926009203/tm264801-1_4seq1.xml","form_type":"4"}},{"id":924456,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2026-02-02T16:05:34.000Z","date":"2026-01-30","kind":"purchase","planned":false,"acquired":true,"shares":5700,"price":0.89,"value":5073.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 5,700 shares of the Issuer's common stock (the \"Shares\") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the \"Common Warrants\") to purchase up to an aggregate of 5,700 Shares."}],"balance_after":33433,"source":{"system":"sec-edgar","filing":"0001104659-26-009203","document":"tm264801-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926009203/tm264801-1_4seq1.xml","form_type":"4"}},{"id":972369,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Warrant","published_at":"2025-12-11T08:31:02.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":5000,"derivative":{"exercise_price":1.04,"exercise_date":"2025-12-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-25-120155","document":"tm2533219-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465925120155/tm2533219-2_4seq1.xml","form_type":"4"}},{"id":972368,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2025-12-11T08:31:02.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.165,"value":5825.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 an aggregate of 5,000 shares of the Issuer's common stock (\"Shares\") at a purchase price of $1.165. The Reporting Person also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 5,000 Shares."}],"balance_after":27733,"source":{"system":"sec-edgar","filing":"0001104659-25-120155","document":"tm2533219-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465925120155/tm2533219-2_4seq1.xml","form_type":"4"}},{"id":1187672,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-03-31T16:31:29.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":13460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":13460,"derivative":{"exercise_price":2.2,"expiration_date":"2035-03-28","underlying":"Common Stock","underlying_shares":13460},"source":{"system":"sec-edgar","filing":"0001104659-25-029920","document":"tm2510809-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465925029920/tm2510809-2_4seq1.xml","form_type":"4"}},{"id":1187671,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2025-03-31T16:31:29.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":3365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":22733,"source":{"system":"sec-edgar","filing":"0001104659-25-029920","document":"tm2510809-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465925029920/tm2510809-2_4seq1.xml","form_type":"4"}},{"id":1385657,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2024-10-16T08:30:13.000Z","date":"2024-10-11","kind":"purchase","planned":false,"acquired":true,"shares":50,"price":2.4638,"value":123.19,"ownership":{"direct":true},"balance_after":19368,"source":{"system":"sec-edgar","filing":"0001104659-24-108962","document":"tm2426059-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924108962/tm2426059-2_4seq1.xml","form_type":"4"}},{"id":1386449,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2024-10-15T08:30:16.000Z","date":"2024-10-10","kind":"purchase","planned":false,"acquired":true,"shares":450,"price":2.61,"value":1174.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.55 to $2.618, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":19318,"source":{"system":"sec-edgar","filing":"0001104659-24-108373","document":"tm2426059-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924108373/tm2426059-1_4seq1.xml","form_type":"4"}},{"id":1558186,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-28T17:59:46.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":13460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":13460,"derivative":{"exercise_price":6.69,"expiration_date":"2024-03-28","underlying":"Common Stock","underlying_shares":13460},"source":{"system":"sec-edgar","filing":"0001104659-24-040645","document":"tm2410009-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924040645/tm2410009-2_4seq1.xml","form_type":"4"}},{"id":1558185,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2024-03-28T17:59:46.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":3365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and shall vest and be settled in the Issuer's common stock (\"Common Stock\") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":18868,"source":{"system":"sec-edgar","filing":"0001104659-24-040645","document":"tm2410009-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924040645/tm2410009-2_4seq1.xml","form_type":"4"}},{"id":1576169,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Tranche B Warrant","published_at":"2024-03-14T20:54:37.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":505,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the Tranche B Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":505,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":505},"source":{"system":"sec-edgar","filing":"0001104659-24-034673","document":"tm248935-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924034673/tm248935-4_4seq1.xml","form_type":"4"}},{"id":1576168,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Tranche A Warrant","published_at":"2024-03-14T20:54:37.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":505,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the Tranche A Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":505,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":505},"source":{"system":"sec-edgar","filing":"0001104659-24-034673","document":"tm248935-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924034673/tm248935-4_4seq1.xml","form_type":"4"}},{"id":1576167,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2024-03-14T20:54:37.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":1010,"price":7.29,"value":7362.9,"ownership":{"direct":true},"balance_after":15503,"source":{"system":"sec-edgar","filing":"0001104659-24-034673","document":"tm248935-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924034673/tm248935-4_4seq1.xml","form_type":"4"}},{"id":1989556,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2023-02-27T18:37:13.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":1000,"price":5.25,"value":5250.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective February 13, 2023, the Issuer completed a 1-for-20 reverse stock split (the \"Reverse Stock Split\") of its outstanding Common Stock. The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":14493,"source":{"system":"sec-edgar","filing":"0001104659-23-026159","document":"tm238004-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465923026159/tm238004-1_4seq1.xml","form_type":"4"}},{"id":2041822,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin. Fin&Acctg. Off"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-01-30T17:21:51.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":539758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on January 30, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":539758,"derivative":{"exercise_price":0.496,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":539758},"source":{"system":"sec-edgar","filing":"0001104659-23-008064","document":"tm234680-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465923008064/tm234680-2_4seq1.xml","form_type":"4"}},{"id":2041821,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin. Fin&Acctg. Off"}}],"security":"Common Stock","published_at":"2023-01-30T17:21:51.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":269879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on January 30, 2023, and which will vest and be settled in common stock in three equal, annual installments beginning on January 30, 2024, January 30, 2025, and January 30, 2026, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":269879,"source":{"system":"sec-edgar","filing":"0001104659-23-008064","document":"tm234680-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465923008064/tm234680-2_4seq1.xml","form_type":"4"}},{"id":2202039,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Common Stock","published_at":"2022-07-26T20:38:04.000Z","date":"2022-07-26","kind":"purchase","acquired":true,"shares":3000,"price":0.3666,"value":1099.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $0.3639 to $0.37. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":72800,"source":{"system":"sec-edgar","filing":"0001437749-22-017793","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774922017793/rdgdoc.xml","form_type":"4"}},{"id":2348701,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-07T22:52:35.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":99600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This employee stock option shall vest and become exercisable with respect to one-twelfth of the total number of shares subject to the options on a quarterly basis (every three months) with the first vest date on May 31, 2022 provided that the reporting person remains in continuous service on each vesting date."}],"balance_after":99600,"derivative":{"exercise_price":1.02,"exercise_date":"2022-05-31","expiration_date":"2032-03-04","underlying":"Common Stock","underlying_shares":99600},"source":{"system":"sec-edgar","filing":"0001437749-22-005421","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774922005421/rdgdoc.xml","form_type":"4"}},{"id":2348700,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Common Stock","published_at":"2022-03-07T22:52:35.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":66300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (RSUs), which represent a contingent right to receive the equivalent number of shares of common stock. These RSUs shall vest with respect to one-third of the total number of shares subject to the RSUs on an annual basis (every 12 months) with the first vest date on February 28, 2023 provided that the reporting person remains in continuous service on each vesting date."}],"balance_after":69800,"source":{"system":"sec-edgar","filing":"0001437749-22-005421","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774922005421/rdgdoc.xml","form_type":"4"}},{"id":2745959,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Common Stock","published_at":"2021-04-19T11:49:12.000Z","date":"2021-04-16","kind":"purchase","acquired":true,"shares":1000,"price":2.0669,"value":2066.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $2.065 to $2.0685. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001437749-21-009187","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774921009187/rdgdoc.xml","form_type":"4"}},{"id":2772414,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Common Stock Warrants","published_at":"2021-03-25T20:44:17.000Z","date":"2021-03-25","kind":"purchase","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Issued in connection with the purchase of shares of common stock on March 25, 2021 as reported above."}],"balance_after":1500,"derivative":{"exercise_price":3.6,"exercise_date":"2021-03-25","expiration_date":"2026-03-25","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001437749-21-007172","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774921007172/rdgdoc.xml","form_type":"4"}},{"id":2772413,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Common Stock","published_at":"2021-03-25T20:44:17.000Z","date":"2021-03-25","kind":"purchase","acquired":true,"shares":1500,"price":3.25,"value":4875.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001437749-21-007172","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774921007172/rdgdoc.xml","form_type":"4"}},{"id":2896233,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-01-26T21:35:48.000Z","date":"2021-01-22","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This employee stock option shall vest in a series of three successive, equal installments beginning with the first anniversary of the grant date."}],"balance_after":60000,"derivative":{"exercise_price":5.44,"exercise_date":"2022-01-22","expiration_date":"2031-01-22","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001437749-21-001284","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774921001284/rdgdoc.xml","form_type":"4"}},{"id":3009581,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Common Stock","published_at":"2020-10-09T12:06:31.000Z","date":"2020-10-07","kind":"purchase","acquired":true,"shares":1000,"price":5.27,"value":5270.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001437749-20-020957","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774920020957/rdgdoc.xml","form_type":"4"}},{"id":3078218,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"officer":true,"officer_title":"SVP & CFO"}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2020-07-22T20:52:11.000Z","date":"2020-07-20","kind":"grant","acquired":true,"shares":211000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in a series of three successive, equal installments beginning with the first anniversary of the grant.  The stock option is an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4)."}],"balance_after":211000,"derivative":{"exercise_price":6.98,"exercise_date":"2021-07-20","expiration_date":"2030-07-20","underlying":"Common Stock","underlying_shares":211000},"source":{"system":"sec-edgar","filing":"0001437749-20-015549","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774920015549/rdgdoc.xml","form_type":"4"}},{"id":3502176,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Fin,Princ Fin&Acct Officer"}}],"security":"Common Stock","published_at":"2019-06-04T20:52:04.000Z","date":"2019-06-03","kind":"tax_withholding","acquired":false,"shares":5516,"price":1.17,"value":6453.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of the restricted stock units."}],"balance_after":82234,"source":{"system":"sec-edgar","filing":"0001209191-19-034359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000120919119034359/doc4.xml","form_type":"4"}},{"id":3502175,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Fin,Princ Fin&Acct Officer"}}],"security":"Common Stock","published_at":"2019-06-04T20:52:04.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":7500,"price":1.16,"value":8700.0,"ownership":{"direct":true},"balance_after":87750,"source":{"system":"sec-edgar","filing":"0001209191-19-034359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000120919119034359/doc4.xml","form_type":"4"}},{"id":3737518,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Fin,Princ Fin&Acct Officer"}}],"security":"Common Stock","published_at":"2018-12-10T21:49:28.000Z","date":"2018-12-06","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. Of the shares underlying the RSU, 25% of the total number of shares subject to the RSU shall vest on June 1, 2019, 25% of the total number of shares subject to the RSU shall vest on December 1, 2019 and 50% of the total number of shares subject to the RSU shall vest on December 6, 2020, until such time as the RSU is vested with respect to all the shares subject to the RSU, subject to the Reporting Person's Contintuous Service (as defined in the 2013 Equity Incentive Plan, as amended) as of each such vesting date."}],"balance_after":80250,"source":{"system":"sec-edgar","filing":"0001209191-18-061799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000120919118061799/doc4.xml","form_type":"4"}},{"id":3827204,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Fin,Princ Fin&Acct Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-04T20:57:15.000Z","date":"2018-08-31","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date."}],"balance_after":52500,"derivative":{"exercise_price":1.8,"expiration_date":"2028-08-31","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001209191-18-049241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000120919118049241/doc4.xml","form_type":"4"}}]}